Alnylam Pharmaceuticals, Inc. (ALNY)

$145.16

-0.16

(-0.11%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Alnylam Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 750.53M → 439.71M (in $), with an average decrease of 41.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 147.75M → -137.87M (in $), with an average decrease of 193.3% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 74.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 240.5%

Performance

  • $144.23
    $146.47
    $145.16
    downward going graph

    0.64%

    Downside

    Day's Volatility :1.53%

    Upside

    0.89%

    downward going graph
  • $143.52
    $218.88
    $145.16
    downward going graph

    1.13%

    Downside

    52 Weeks Volatility :34.43%

    Upside

    33.68%

    downward going graph

Returns

PeriodAlnylam Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-21.85%
-0.7%
0.0%
6 Months
-11.97%
6.6%
0.0%
1 Year
-27.94%
3.7%
-1.5%
3 Years
5.76%
14.0%
-21.8%

Highlights

Market Capitalization
18.6B
Book Value
- $1.75
Earnings Per Share (EPS)
-3.53
PEG Ratio
-0.49
Wall Street Target Price
222.68
Profit Margin
-24.08%
Operating Margin TTM
-26.47%
Return On Assets TTM
-4.78%
Return On Equity TTM
-1500.66%
Revenue TTM
1.8B
Revenue Per Share TTM
14.64
Quarterly Revenue Growth YOY
31.2%
Gross Profit TTM
868.6M
EBITDA
-228.1M
Diluted Eps TTM
-3.53
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.11
EPS Estimate Next Year
-1.76
EPS Estimate Current Quarter
-1.32
EPS Estimate Next Quarter
-1.3

Analyst Recommendation

Buy
    75%Buy
    24%Hold
    0
    0%Sell
Based on 33 Wall street analysts offering stock ratings for Alnylam Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 33 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
25
26
25
Hold
8
6
7
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 53.4%

Current $145.16
Target $222.68

Company Financials

FY18Y/Y Change
Revenue
74.9M
↓ 16.69%
Net Income
-761.5M
↑ 55.13%
Net Profit Margin
-1.0K%
↓ 470.63%
FY19Y/Y Change
Revenue
219.8M
↑ 193.36%
Net Income
-886.1M
↑ 16.37%
Net Profit Margin
-403.24%
↑ 613.34%
FY20Y/Y Change
Revenue
492.9M
↑ 124.28%
Net Income
-858.3M
↓ 3.14%
Net Profit Margin
-174.15%
↑ 229.09%
FY21Y/Y Change
Revenue
844.3M
↑ 71.31%
Net Income
-852.8M
↓ 0.64%
Net Profit Margin
-101.01%
↑ 73.14%
FY22Y/Y Change
Revenue
1.0B
↑ 22.88%
Net Income
-1.1B
↑ 32.64%
Net Profit Margin
-109.04%
↓ 8.03%
FY23Y/Y Change
Revenue
1.8B
↑ 76.23%
Net Income
-440.2M
↓ 61.08%
Net Profit Margin
-24.08%
↑ 84.96%
Q3 FY22Q/Q Change
Revenue
264.3M
↑ 17.56%
Net Income
-405.9M
↑ 46.33%
Net Profit Margin
-153.58%
↓ 30.19%
Q4 FY22Q/Q Change
Revenue
335.0M
↑ 26.76%
Net Income
-207.5M
↓ 48.88%
Net Profit Margin
-61.93%
↑ 91.65%
Q1 FY23Q/Q Change
Revenue
319.3M
↓ 4.7%
Net Income
-174.1M
↓ 16.09%
Net Profit Margin
-54.53%
↑ 7.4%
Q2 FY23Q/Q Change
Revenue
318.8M
↓ 0.17%
Net Income
-276.0M
↑ 58.54%
Net Profit Margin
-86.59%
↓ 32.06%
Q3 FY23Q/Q Change
Revenue
750.5M
↑ 135.46%
Net Income
147.8M
↓ 153.53%
Net Profit Margin
19.69%
↑ 106.28%
Q4 FY23Q/Q Change
Revenue
439.7M
↓ 41.41%
Net Income
-137.9M
↓ 193.31%
Net Profit Margin
-31.35%
↓ 51.04%
FY18Y/Y Change
Total Assets
1.6B
↓ 21.05%
Total Liabilities
272.8M
↑ 19.51%
FY19Y/Y Change
Total Assets
2.4B
↑ 52.09%
Total Liabilities
956.4M
↑ 250.55%
FY20Y/Y Change
Total Assets
3.4B
↑ 42.25%
Total Liabilities
2.4B
↑ 149.97%
FY21Y/Y Change
Total Assets
3.6B
↑ 6.93%
Total Liabilities
3.1B
↑ 27.78%
FY22Y/Y Change
Total Assets
3.5B
↓ 2.66%
Total Liabilities
3.7B
↑ 21.26%
FY23Y/Y Change
Total Assets
3.8B
↑ 7.99%
Total Liabilities
4.1B
↑ 9.34%
Q3 FY22Q/Q Change
Total Assets
3.5B
↑ 6.15%
Total Liabilities
3.6B
↑ 14.22%
Q4 FY22Q/Q Change
Total Assets
3.5B
↑ 0.31%
Total Liabilities
3.7B
↑ 2.82%
Q1 FY23Q/Q Change
Total Assets
3.4B
↓ 4.35%
Total Liabilities
3.7B
↓ 1.44%
Q2 FY23Q/Q Change
Total Assets
3.4B
↑ 0.31%
Total Liabilities
3.8B
↑ 4.36%
Q3 FY23Q/Q Change
Total Assets
3.8B
↑ 12.83%
Total Liabilities
4.0B
↑ 5.1%
Q4 FY23Q/Q Change
Total Assets
3.8B
↓ 0.24%
Total Liabilities
4.1B
↑ 1.14%
FY18Y/Y Change
Operating Cash Flow
-562.6M
↑ 46.98%
Investing Cash Flow
272.9M
↓ 194.0%
Financing Cash Flow
65.5M
↓ 94.18%
FY19Y/Y Change
Operating Cash Flow
-278.4M
↓ 50.51%
Investing Cash Flow
-417.7M
↓ 253.03%
Financing Cash Flow
823.2M
↑ 1157.35%
FY20Y/Y Change
Operating Cash Flow
-615.0M
↑ 120.87%
Investing Cash Flow
-435.5M
↑ 4.27%
Financing Cash Flow
995.0M
↑ 20.87%
FY21Y/Y Change
Operating Cash Flow
-641.7M
↑ 4.35%
Investing Cash Flow
-273.3M
↓ 37.25%
Financing Cash Flow
1.2B
↑ 25.34%
FY22Y/Y Change
Operating Cash Flow
-541.3M
↓ 15.65%
Investing Cash Flow
169.4M
↓ 161.97%
Financing Cash Flow
425.8M
↓ 65.86%
Q3 FY22Q/Q Change
Operating Cash Flow
-115.3M
↓ 6.14%
Investing Cash Flow
313.9M
↑ 119.82%
Financing Cash Flow
297.0M
↑ 879.08%
Q4 FY22Q/Q Change
Operating Cash Flow
-132.0M
↑ 14.48%
Investing Cash Flow
-139.9M
↓ 144.57%
Financing Cash Flow
63.4M
↓ 78.64%
Q1 FY23Q/Q Change
Operating Cash Flow
-166.5M
↑ 26.14%
Investing Cash Flow
-76.2M
↓ 45.52%
Financing Cash Flow
46.4M
↓ 26.9%
Q2 FY23Q/Q Change
Operating Cash Flow
-59.0M
↓ 64.57%
Investing Cash Flow
-8.7M
↓ 88.57%
Financing Cash Flow
53.4M
↑ 15.15%
Q3 FY23Q/Q Change
Operating Cash Flow
359.4M
↓ 709.32%
Investing Cash Flow
-10.8M
↑ 23.54%
Financing Cash Flow
33.1M
↓ 37.94%

Technicals Summary

Sell

Neutral

Buy

Alnylam Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-1.42%
-11.97%
-27.94%
5.76%
77.07%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-4.11
-15.01
-0.05
NA
-1.75
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$18.6B
77.07%
NA
-24.08%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Capital World Investors

    12.84%

  • Vanguard Group Inc

    9.48%

  • FMR Inc

    8.19%

  • BlackRock Inc

    6.77%

  • Wellington Management Company LLP

    5.73%

  • Baillie Gifford & Co Limited.

    5.53%

Corporate Announcements

  • Alnylam Pharmaceuticals, Inc. Earnings

    Alnylam Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

Organization
Alnylam Pharmaceuticals, Inc.
Employees
2100
CEO
Dr. Yvonne L. Greenstreet M.B.A., MBChB
Industry
Health Technology

Discover More

FAQs